Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkin's disease, can produce lung toxicity leading to fibrosis. There is increasing evidence of the involvement in the fibrosing process of different cytokines and growth factors such as TNF-alfa, IL-1 beta, TGF-beta and PDGF.
Material and Methods
In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay. Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months.
Results
DLCO decreased at the end of the combined treatment and then remained constantly decreased. TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-1 beta significantly increased after the completion of the combined treatment and after a follow-up of 6–months and then declined to normal values after 12 months. The serum concentration of the cytokine was significantly higher in patients who had a DLCO <75% of predicted after 1 year than in patients with a DLCO >75%.
Conclusions
The results indicate a potential role of IL-1 beta in the pathogenesis of chemoradiotherapy-induced lung toxicity, which needs to be confirmed in a larger patient population.
EghbaliH., BonichonF., DavidB., RojouanJ., AudebertA.A., BlancC.M., ZittounR., HoerniB., NajmanA.: Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients.Radiother Oncol, 18: 127–136, 1990.
2.
CossetJ.M., Henry-AmarM., MeerwaldJ.H.: Long-term toxicity of early stage of Hodgkin's disease therapy: the EORTC experience.Ann Oncol, 2 Suppl, 2: 77–82, 1991.
3.
BriceP., TredanielJ., MonsuezJ.J., MarolleauJ.P., FermeC., HennequinC., FrijaJ., GisselbrechtC., BoironM.: Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favourable Hodgkin's disease.Ann Oncol, 2 suppl, 2: 73–76, 1991.
4.
HorningS.J., AdhikariA., RizkN., HoppeR.T., OlshenR.A.: Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study.J Clin Oncol, 12: 297–305, 1994.
5.
HirschA., Vander ElsN., StrausD.J., GomezE.G., LeunqD., PortlockC.S., YahalomJ.: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early stage Hodgkin's disease.J Clin Oncol, 14: 1297–1305, 1996.
6.
VillaniF., De MariaP., BonfanteV., VivianiS., LaffranchiA., Dell'OcaI., Di RussoA., ZaniniM.: Late pulmonary toxicity after treatment for Hodgkin's disease.Anticancer Res, 17: 4739–4742, 1997.
7.
LagrangeJ.P.: Long-term toxicity of the treatment of Hodgkin's disease.Ann Oncol, 9 Suppl, 1: 133–136, 1998.
8.
VivianiS., BonfanteV., SantoroA., ZaniniM., DevizziL., Di RussoA., SonciniF., VillaniF., RagniG., ValagussaP., BonadonnaG.: Long-term results of a intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.Cancer J Sci Am, 5: 275–282, 1999.
9.
BonadonnaG., BonfanteV., VivianiS., Di RussoA., VillaniF., ValagussaP.: ABVD plus subtotal nodal versus involved field radiotherapy in early-stage Hodkgin's disease: long-term results.J Clin Oncol, 22: 2835–2841, 2004.
10.
MartinetY., MenardO., VaillantP., VignaudJ.M., MartinetN.: Cytokines in human lung fibrosis.Arch Toxicol, 18: 127–139, 1996.
11.
WardP.A., HunninghakeG.W.: Lung inflammatory and fibrosis.Am J Respir Crit Care Med, 157: S123–S129, 1998.
12.
CokerR.K., LaurentG.J.: Pulmonary fibrosis: cytokines in the balance.Eur Respir J, 11: 1218–1221, 1998.
SimeP.J., O'ReillyK.M.A.: Short analytical review. Fibrosis of the lung and other tissue: new concepts in pathogenesis and treatment.Clin Immunol, 99: 308–319, 2001.
15.
StrieterR.M.: Mechamism of pulmonary fibrosis: conference summary.Chest, 120: 77S–85S, 2001.
16.
KellyM., KolbM., BonniaudP., GauldieJ.: Re-evaluation of fibrogenic cytokines in lung fibrosis.Curr Pharm Des, 9: 39–49, 2003.
17.
AntoniuK.M., AlexandrakisM.G., SiafakasN.M., BourosD.: Cytokine network in the pathogenesis of idiopatic pulmonary fibrosis.Sarcoidosis Vasc Diffuse Lung Dis, 22: 91–104, 2005.
18.
AgostiniC., GuerrieriC.: Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis.Proc Am Thorac Soc, 3: 357–363, 2006.
19.
OgilvieC.M., ForsterR.E., BlakemoreW.S., MortonJ.W.: A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide.J Clin Invest, 36: 1–17, 1957.
DinakaraP., BlumenthalW.S., JohnstonR.F., KaufmanL.A., SolnickP.B.: The effect of anemia on pulmonary diffusing capacity with derivation of a correct equation.Am Rev Respir Dis, 102: 965–969, 1970.
22.
RoughtonF.J.W., ForsterR.E.: Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries.J Appl Physiol, 2: 290–302, 1957.
23.
ElsN.J.V., SorhageF., BachA.M., StraussD.J., WhiteD.A.: Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease.Chest, 117: 1256–1261, 2000.
24.
PiquetP.E., VesinC.: Treatment by human recombinant soluble TNF receptors of pulmonary fibrosis induced by bleomycin or silica in mice.Eur Respir J, 7: 515–518, 1994.
25.
AgostiniC., ZambelloR., SancettaR., CeruttiA., MilaniA., TassinariC., FaccoM., CiprianiA., TrentinL., SemenzatoG.: Expression of tumor necrosis factor-receptors subfamily members by lung T lymphocytes in interstitial lung disease.Am J Respir Crit Care Med, 153: 1359–1362, 1996.
26.
ZhangK., Gharace-KermaniM., McGarryB., RemickD., PhanS.H.: TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis.J Immunol, 158: 954–959, 1997.
27.
SleijferS., VujaskovicZ., LiniburgP.C., Schraffordt KoopsH., MulderN.H.: Induction of tumor necrosis factor-alfa as a cause of bleomycin-related toxicity.Cancer, 82: 970–974, 1998.
28.
LundbladL.K.A., Thompson-FigueroaJ., LeclairT., SullivanM.J., PoynterM.E., IrvinC.G., BatesJ.H.: Tumor necrosis factor-alfa overexpression in lung disease. A single cause behind a complex phenotype.Am J Respir Crit Care Med, 171: 1363–1370, 2005.
29.
BroekelmannT.J., LimperA.H., ColbyT.V., McDonaldJ.A.: Transforming growth factor-beta1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.Proc Natl Acad Sci Usa, 88: 6642–6646, 1991.
30.
EickelbergO., KohlerE., ReichenbergerF., BertschinS., WoodtliT., ErneP., PerruchodA.P., RothM.: Extracellular matrix deposition by primary human lung fibroblast in response to TGF-β1 and TGF-β2.Am J Physiol, 276: L814–L824, 1999.
31.
SelmanM., RuizV., CabreraS., SeguraL., RamirezR., BarniosR., PardoA.: TIMP-1, -2, 3 and 4 in idiopathic pulmonary fibrosis: a prevailing nondegradative lung microenvironment?Am J Physiol Lung Cell Mol Physiol, 279: L562–L574, 2000.
32.
YongS.J., AdlakhaA., LimperA.H.: Circulating transforming growth factor-beta1. A potential marker of disease activity during idiopathic pulmonary fibrosis.Chest, 120: 68S–70S, 2001.
ShephardD.: Transforming growth factor-beta. A central modulator of pulmonary and airway inflammation and fibrosis.Proc Am Thorac Soc, 3: 413–417, 2006.
35.
MarinelliW.A., PolunovskyV.A., HarmonK.R., BittermannP.B.: Role of platelet growth factor in pulmonary fibrosis.Am J Respir Crit Care Med, 5: 503–504, 1991.
TadaH., OgushiF., TaniK., NishiotaY., MiyataJ.Y., SatoK., AsanoT., SoneS.: Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis.Radiat Res, 159: 805–811, 2003.
38.
ZhuoY., ZhangJ., LoboyM., LaskyJ.A.: Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis.Am J Physiol Lung Cell Mol Physiol, 286: 182–188, 2004.
39.
PanL.H., OhraniH., YamauchiK., NajuraH.: Co-expression of TNF-alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis.Pathol Int, 46: 91–99, 1996.
40.
KolbM., MargettsP.J., AnthonyD.C., PitossiF., GauldieJ.: Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.J Clin Invest, 107: 1529–1536, 2001.
41.
LappalainenU., WhitsettJ.A., WestS.E., TichelaarJ.W., BryK.: Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodelling in the adult murine lung. Am.J Respir Cell Mol Biol, 32: 311–318, 2005.
42.
LiuW., DingI., ChenK., OlschowkaJ., XuD., MorrowG.R., OkunieffP.: Interleukin 1 beta (IL-1β) signalling is a critical component of radiation-induced skin fibrosis.Radiat Res, 165: 181–191, 2006.
43.
PiguetP.F., VesinC., GrauG.E., ThompsonR.C.: Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.Cytokine, 5: 57–61, 1993.
